Valion Bio Announces Completion of Oral Mucosal Formulation Work for Entolimod

What Happened

• Valion Bio, Inc. announced on September 30, 2026 (filed via Form 8-K) that it completed formulation work to develop a novel oral mucosal formulation of its drug candidate Entolimod using Shear Kershman Laboratories’ proprietary BioViscid™ drug‑delivery platform. The announcement was made public in a press release filed as Exhibit 99.1 to the 8-K.

Key Details

• Date of announcement and filing: September 30, 2026.
• Drug candidate: Entolimod; formulation target: oral mucosal delivery.
• Development partner/platform: Shear Kershman Laboratories’ proprietary BioViscid™ drug‑delivery platform.
• Disclosure: Press release included as Exhibit 99.1 to the Current Report on Form 8-K.

Why It Matters

• Completion of formulation work is a tangible development milestone reported by the company and indicates progress toward an oral mucosal form of Entolimod, which could affect future development and regulatory planning. The company publicly disclosed this progress via an 8-K and press release, and the filing includes standard forward‑looking statement language.